Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 annual meeting.
In December 2024, the company announced DAZALS did not meet its primary endpoint, which was the change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to those who received a placebo.
https://finance.yahoo.com/news/corcept-therapeutics-therapy-fails-primary-152035541.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.